Table of Contents
Personalizing an insulin plan is one of the most critical components of effective diabetes management. Every person with diabetes has unique physiological characteristics, lifestyle patterns, and treatment goals that require individualized insulin therapy. Connectivity of these devices has created a diabetes ecosystem that provides immediate feedback to patients about their health status and enables health care providers to make informed decisions about therapy adjustments. This comprehensive guide explores evidence-based approaches to customize insulin regimens, optimize dosing strategies, and leverage modern technology for better health outcomes.
Understanding the Foundation of Personalized Insulin Therapy
Personalized insulin therapy goes far beyond simply prescribing a standard dose. It requires a comprehensive understanding of how individual factors influence insulin requirements and blood glucose patterns. The goal is to mimic the body’s natural insulin production as closely as possible while accommodating the realities of daily life.
The Importance of Individual Assessment
Before developing a personalized insulin plan, healthcare providers must conduct a thorough assessment of multiple factors. Understanding a person’s lifestyle, dietary habits, physical activity levels, sleep patterns, and stress levels is essential. These elements directly influence insulin sensitivity and glucose metabolism throughout the day.
Meal patterns play a particularly significant role in insulin planning. Some individuals eat three structured meals daily, while others prefer smaller, more frequent meals or follow intermittent fasting protocols. Physical activity varies widely among individuals, from sedentary lifestyles to intense athletic training. Each pattern requires different insulin dosing strategies to maintain optimal glucose control.
Work schedules, shift work, travel patterns, and social commitments also impact insulin requirements. A personalized plan must be flexible enough to accommodate these variables while maintaining consistent glucose control. Healthcare providers evaluate all these aspects to develop a truly individualized approach.
Physiological Factors Affecting Insulin Needs
Beyond lifestyle considerations, several physiological factors influence insulin requirements. Body weight and composition significantly affect insulin sensitivity, with type 1 patients requiring approximately 0.4 units/kg/day; type 2 patients varying in their insulin resistance and may require from 0.5 to 2 units/kg/day. Age, hormonal fluctuations, illness, medications, and stress all impact how the body responds to insulin.
Insulin sensitivity can vary throughout the day due to circadian rhythms and hormonal patterns. Many people experience the “dawn phenomenon,” where blood glucose rises in the early morning hours due to increased cortisol and growth hormone secretion. Others may have increased insulin sensitivity during certain times of day or after physical activity. Identifying these patterns is crucial for optimizing insulin timing and dosing.
Types of Insulin and Their Strategic Use
Modern insulin therapy utilizes different insulin types, each designed to serve specific functions in glucose management. Understanding these insulins and how to combine them effectively is fundamental to personalized therapy.
Rapid-Acting Insulin Analogs
Rapid-acting insulins, including lispro, aspart, and glulisine, begin working within 10-15 minutes of injection and peak in approximately 1-2 hours. Lispro, aspart, or glulisine are given with each meal or immediately after eating (can base on amount eaten). These insulins are ideal for covering meals and correcting high blood glucose levels.
The flexibility of rapid-acting insulins makes them particularly valuable for personalized therapy. They can be dosed immediately before, during, or even after meals, which is especially helpful for individuals with unpredictable appetites or eating patterns. This flexibility also allows for dose adjustments based on actual food consumption rather than anticipated intake.
Short-Acting Regular Insulin
Regular insulin has a slower onset than rapid-acting analogs, beginning to work in 30 minutes and peaking in 2-3 hours. Rapid acting insulins should be just before meal. Short acting insulin needs to be taken 30 minute before meals. While less commonly used today, regular insulin remains an option for some patients, particularly those who need a longer duration of action for meals with extended absorption.
Long-Acting Basal Insulin
Long-acting insulins such as glargine, detemir, and degludec provide steady background insulin coverage for 12-24 hours or longer. After the introduction of insulin degludec and long-acting insulin glargine (U300), a new era has opened in basal insulin management. These insulins mimic the body’s baseline insulin secretion and help maintain stable glucose levels between meals and overnight.
Basal insulin forms the foundation of most insulin regimens. The goal is to provide enough background insulin to keep glucose stable during fasting periods without causing hypoglycemia. Proper basal insulin dosing means that glucose levels should remain relatively stable overnight and between meals when no food is consumed.
Emerging Ultra-Long-Acting Insulins
Weekly basal insulins are engineered for ultra-long action through molecular modifications that extend their half-life and maintain stable pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Once-weekly insulins have been in development in the U.S. for years, but they have yet to receive FDA clearance. Novo Nordisk completed studies for their once-weekly insulin icodec, and Lilly’s efsitora alfa is in phase 3 of clinical trials. Weekly basal insulin could mean a significantly reduced diabetes management burden for millions of people.
Intermediate-Acting NPH Insulin
NPH (Neutral Protamine Hagedorn) insulin has an intermediate duration of action, typically lasting 12-18 hours with a pronounced peak 4-6 hours after injection. While newer basal insulins have largely replaced NPH in many treatment plans, it remains a cost-effective option for some patients. NPH requires more careful timing with meals due to its peak action.
Premixed Insulin Formulations
Premixed insulins combine rapid- or short-acting insulin with intermediate-acting insulin in fixed ratios such as 70/30 or 75/25. These formulations simplify insulin administration for some patients but offer less flexibility for dose adjustments. In studies with type 2 diabetics, 70/30 has typically been initiated at doses of 0.2 – 0.6 units/kg/day, with two-thirds of the daily dose given before breakfast and one-third before dinner. The daily dose can then be adjusted up or down in increments of 10%, depending on blood sugar readings.
Inhaled Insulin Options
For adults with T1D or T2D, inhaled insulin has demonstrated comparable efficacy to rapid-acting injectable insulin, with added benefits such as reduced weight gain and improved patient satisfaction. Recent studies, including the INHALE-1 trial, which was presented at the American Diabetes Conference in 2025, have extended these findings to pediatric populations. In children aged 4–17 years old with T1D, inhaled insulin showed non-inferior glycemic control compared to injected analogs. This alternative delivery method provides another option for personalizing insulin therapy based on patient preferences and needs.
Insulin Regimen Selection and Optimization
Choosing the right insulin regimen is a critical decision that should be based on individual needs, capabilities, and treatment goals. Several regimen options exist, each with distinct advantages and considerations.
Basal-Only Regimen
A basal-only regimen uses long-acting insulin once or twice daily to provide background insulin coverage. This approach is often the starting point for people with type 2 diabetes who need insulin therapy. It’s typically combined with oral medications or GLP-1 receptor agonists to manage postprandial glucose excursions.
The simplicity of basal-only therapy makes it an attractive option for insulin initiation. Patients take one injection daily, usually at bedtime, which minimizes the complexity and burden of insulin therapy. However, this regimen may not provide adequate control for individuals with significant postprandial glucose elevations or those with type 1 diabetes.
Basal-Bolus Regimen
Most people with type 1 will be advised to start a basal-bolus or multiple daily injection (MDI) regimen. This is the most flexible way of insulin management; ideal if you have a busy life, with lots of different activities going on. This regimen combines long-acting basal insulin with rapid-acting insulin before meals, allowing for precise glucose management throughout the day.
The basal-bolus approach most closely mimics physiological insulin secretion. Basal insulin provides steady background coverage, while bolus doses address the glucose rise from meals. This regimen offers maximum flexibility for varying meal times, sizes, and carbohydrate content. It also allows for correction doses to bring down elevated glucose levels between meals.
While basal-bolus therapy requires multiple daily injections and more frequent glucose monitoring, it provides the best opportunity for achieving tight glucose control while maintaining lifestyle flexibility. This regimen is standard for type 1 diabetes and increasingly used for type 2 diabetes when other approaches prove insufficient.
Premixed Insulin Regimen
Premixed insulin regimens involve taking fixed-ratio insulin combinations twice daily, typically before breakfast and dinner. This approach simplifies insulin administration but requires more consistent meal timing and carbohydrate intake. To encourage patient buy-in, it may be more strategic initially to begin with a regimen that will be the most acceptable to the patient even if it may not be the clinician’s first choice (e.g., pre-mixed instead of basal-bolus regimen).
Evidence-Based Insulin Dose Calculation Methods
Calculating appropriate insulin doses requires understanding several key concepts and formulas. These evidence-based methods help ensure safe and effective insulin dosing tailored to individual needs.
Total Daily Dose Estimation
The total daily dose (TDD) of insulin serves as the foundation for calculating other insulin parameters. For insulin-naive patients, the initial TDD is typically calculated based on body weight. Type 1 patients require approximately 0.4 units/kg/day; type 2 patients vary in their insulin resistance and may require from 0.5 to 2 units/kg/day. These are starting points that require adjustment based on individual response.
For patients already using insulin, the TDD is simply the sum of all insulin doses taken in a 24-hour period, including both basal and bolus insulin. This figure becomes the basis for calculating insulin sensitivity factors and carbohydrate ratios.
Insulin Sensitivity Factor (Correction Factor)
The insulin sensitivity factor (ISF), also called the correction factor, indicates how much one unit of rapid-acting insulin will lower blood glucose. Correction Factor (CF) = 1800 / 60 = 30. If pre-meal glucose = 250, blood glucose is 150 mg/dl above goal of 100; Correction is 150/30 = 5 units. Give 5 units in addition to the meal dose.
The “1800 rule” is commonly used to calculate ISF: divide 1800 by the total daily dose of insulin. For example, if someone uses 60 units of insulin daily, their ISF would be 1800 ÷ 60 = 30, meaning one unit of rapid-acting insulin should lower their glucose by approximately 30 mg/dL. Some practitioners use the “1500 rule” for regular insulin or for individuals who are more insulin resistant.
The ISF helps determine correction doses when glucose is above target. If the target glucose is 100 mg/dL and the current reading is 250 mg/dL, the correction would be (250 – 100) ÷ 30 = 5 units. This calculation allows for precise adjustments to bring glucose back to target range.
Insulin-to-Carbohydrate Ratio
The insulin-to-carbohydrate ratio (I:C ratio) determines how much rapid-acting insulin is needed to cover a specific amount of carbohydrate. Insulin to Carbohydrate Ratio (I:C Ratio): 500/50 = 1:10 units. For a 60 gm carbohydrate meal = 60/10 = take 6 units.
The “500 rule” provides a starting point for calculating I:C ratios: divide 500 by the total daily dose of insulin. If the TDD is 50 units, the I:C ratio would be 500 ÷ 50 = 10, meaning one unit of insulin covers 10 grams of carbohydrate. To dose for a meal containing 60 grams of carbohydrate, the calculation would be 60 ÷ 10 = 6 units of rapid-acting insulin.
I:C ratios often vary throughout the day due to changing insulin sensitivity. Many people require more insulin per gram of carbohydrate at breakfast due to dawn phenomenon effects, while they may need less insulin at other meals. Personalized therapy involves determining separate I:C ratios for breakfast, lunch, and dinner based on glucose response patterns.
Simplified Meal-Based Dosing
Not all patients can or want to count carbohydrates precisely. These adjustments can be to either reduce insulin (subtract), increase insulin (add), or make no adjustment (no change) to the current prescribed dose based on the patient’s premeal glucose value and estimated meal size: smaller than usual (small), usual size (usual), or larger than usual (large). Note that we specifically chose not to use the term “medium” because patients’ definitions of small, medium, and large can vary dramatically.
Calculating accurate mealtime insulin doses is a common challenge for patients because of inadequate training. Deficits in numeracy are common among individuals with diabetes, strongly associated with poor glycemic control, and compounded by low competency in carbohydrate counting. Given the growing prevalence of diabetes and the increasing proportion of adults with type 2 diabetes who are not meeting their glycemic targets, new approaches to initiating and intensifying insulin therapy in type 2 diabetes are needed. In this article, we describe a safe and simple insulin titration algorithm that addresses many of the obstacles.
This approach establishes a usual mealtime dose and then adjusts it up or down based on meal size and premeal glucose. For example, if the usual breakfast dose is 8 units, the patient might take 6 units for a smaller meal, 8 units for a usual meal, or 10 units for a larger meal, with additional adjustments based on the premeal glucose reading.
Strategic Insulin Dose Adjustment Protocols
Adjusting insulin doses appropriately is essential for optimizing glucose control while minimizing the risk of hypoglycemia. Evidence-based adjustment strategies provide a systematic approach to dose modifications.
Basal Insulin Adjustment Strategies
The only insulin working overnight is your basal insulin. Glucose level should stay fairly steady overnight if the dose is correct. If glucose consistently rises overnight, it is likely that your basal insulin dose is too low if glucose consistently falls overnight, it is an indication that your basal insulin dose may be too high.
Basal insulin dose adjustments are made at the end of each week and used for the nightly bedtime basal insulin dose throughout the next week. The dose adjustments are made after a retrospective review of morning glucose results recorded during the prior week. These adjustments are made based on glucose values that indicate an increased risk for hypoglycemia or hyperglycemia.
A common basal adjustment protocol involves reviewing fasting glucose readings over several days. If fasting glucose consistently runs above target, basal insulin is increased by 10-15% or 2-4 units, depending on the current dose. If fasting glucose is consistently below target or hypoglycemia occurs, basal insulin is decreased by a similar amount. May consider self titrating basal insulin by increasing dose 1 unit every day until average fasting glucose is < 130, if that is easier for the patient to understand. Self titration of small doses may be easiest for patients using insulin pens.
Basal insulin should be adjusted gradually and systematically. On the other hand, you should only adjust your basal (long-acting insulin) doses occasionally, and this is usually worth discussing with your diabetes team. Making large, frequent changes increases the risk of overcorrection and glucose instability. Patience is essential when optimizing basal insulin doses.
Bolus Insulin Adjustment Strategies
Your short-acting insulin (bolus insulin) is what you will be adjusting on a day-to-day basis, depending on the amount of carbohydrate you eat and in response to your blood glucose levels. If your blood glucose is regularly rising after meals, then it probably means you are not taking enough insulin to cover the carbohydrate eaten in the meal.
Bolus insulin adjustments occur more frequently than basal adjustments. Daily adjustments are made based on premeal glucose levels, anticipated carbohydrate intake, and planned physical activity. You are likely to be adjusting your quick-acting insulin doses on a daily basis.
Mealtime insulin dose adjustments are also made at the end of each week and used for each subsequent week. These are calculated based on the prior week’s midday mealtime (for morning meal), evening mealtime (for midday meal), and bedtime glucose (for evening meal) patterns from the previous week. These newly calculated doses are then adjusted for each meal during the week based on meal size and glucose level at the time of the meal.
When postprandial glucose consistently runs high after a particular meal, the I:C ratio for that meal may need adjustment. If glucose is consistently elevated 2-3 hours after breakfast despite using the calculated I:C ratio, the ratio may need to be changed from 1:10 to 1:8, meaning more insulin per gram of carbohydrate. Conversely, if postprandial glucose consistently drops too low, the ratio may need to be adjusted to require less insulin per gram of carbohydrate.
Pattern Management and Trend Analysis
Identifying repeating patterns is so important; Is your blood glucose always high or always low at a certain time of the day? or after a certain type of food or exercise? Adjust your insulin proactively to stop it from happening again.
Effective insulin adjustment requires looking beyond individual glucose readings to identify patterns and trends. Rather than reacting to every high or low glucose value, successful diabetes management involves analyzing data over several days to identify consistent patterns that indicate the need for systematic dose changes.
Pattern management involves reviewing glucose data to answer specific questions: Is fasting glucose consistently elevated? Do glucose levels spike after particular meals? Is there a pattern of afternoon lows? Does glucose rise overnight? Answering these questions guides targeted insulin adjustments rather than random dose changes.
Gradual Titration Principles
Insulin regimens should be adjusted every three or four days until targets of self-monitored blood glucose levels are reached. A fasting and premeal blood glucose goal of 80 to 130 mg per dL and a two-hour postprandial goal of less than 180 mg per dL are recommended.
Remember that insulin will lower your blood glucose, so if you take too much insulin your blood glucose can go too low and if you take too little it can go too high. Regular blood glucose testing and recording the results will help you to see how your blood glucose levels change and allow you to improve your overall diabetes management.
Studies consistently support gradual insulin adjustments to minimize risks and optimize control. Making small, incremental changes allows time to observe the full effect of each adjustment before making additional modifications. This approach reduces the risk of overcorrection, which can lead to hypoglycemia or glucose variability.
Insulin doses must be reevaluated on a daily basis and orders should be rewritten in order to achieve goals and to adapt to the patients’ changing clinical situation. However, systematic dose changes should typically occur every 3-7 days after sufficient data has been collected to identify clear patterns.
Patient-Adjusted Versus Healthcare Professional-Adjusted Dosing
An important consideration in personalizing insulin therapy is determining who makes dose adjustments—the patient or the healthcare provider. Both approaches have merits and evidence supporting their use.
Patient Self-Adjustment
Patient‐adjusted insulin dosing requires patients to adjust the insulin dose themselves based on the blood glucose level. This intervention may empower people with T2DM using insulin to manage their condition at home. Patients will monitor their blood glucose levels and adjust the insulin dose accordingly.
Patient‐adjusted insulin dosing might be more empowering and cost‐effective as fewer contacts with health‐professionals are needed. Health professional‐adjusted insulin dosing however might be safer given the greater clinical experience of healthcare providers. Some studies indicate that self‐adjustment is equivalent to health professional‐directed titration in terms of reaching target HbA1c, whereas others indicate that self‐adjustment is more effective albeit with a greater incidence of hypoglycaemia.
Patient self-adjustment empowers individuals to take active control of their diabetes management. It allows for immediate dose modifications based on real-time circumstances such as meal size variations, activity changes, or illness. This approach can lead to better glucose control by enabling rapid responses to changing conditions.
However, patient self-adjustment requires comprehensive education, numeracy skills, and confidence in making dosing decisions. Not all patients are comfortable with or capable of this level of self-management. Success depends on thorough training in pattern recognition, dose calculation, and hypoglycemia prevention.
Healthcare Professional-Guided Adjustment
Health professional‐adjusted insulin dosing refers to any interventions that involve dose adjustment by the health professional, including face to face consultations, advice through telephone or electronic means.
Healthcare professional-guided adjustment involves regular review of glucose data by clinicians who make systematic dose recommendations. This approach may be safer for patients who lack confidence in self-adjustment or have complex medical conditions requiring expert oversight. It ensures that dose changes are made with clinical expertise and consideration of the complete medical picture.
In the most recent competencies published by the Association of Diabetes Care and Education Specialists in 2020, under the domain of monitoring, it states that a CDCES can interpret the data from glucose monitoring tools and translate the data findings into actionable recommendations based on the plan of care. We report data from our Pediatric CDCES insulin dosing protocol demonstrating its safety and effectiveness. The CDCES team used their competencies established with CDCES certification to help families interpret the data from the CGM.
Hybrid Approaches
Many successful insulin management programs use hybrid approaches that combine patient self-adjustment for daily variations with healthcare professional guidance for systematic dose changes. Patients make day-to-day adjustments for meals and corrections while healthcare providers review patterns periodically and recommend changes to basal doses or I:C ratios.
This collaborative approach leverages the strengths of both methods. Patients gain autonomy and flexibility for daily management while benefiting from expert oversight for more significant therapeutic decisions. Our diabetes team’s short-term goal—especially for the CDCESs—is to help guardians learn how to adjust insulin doses to meet glycemic targets. Long-term, we aim to support newly diagnosed youth with T1DM in becoming confident with self-management.
Advanced Glucose Monitoring Technologies
Modern glucose monitoring technologies have revolutionized the ability to personalize insulin therapy. These tools provide unprecedented insight into glucose patterns and enable more precise insulin adjustments.
Continuous Glucose Monitoring Systems
Transitioning from self-monitoring of blood glucose to continuous glucose monitoring in combination with a mHealth app improves glycemic control in people with type 1 and type 2 diabetes. Continuous glucose monitoring (CGM) systems measure interstitial glucose levels every 1-5 minutes, providing a comprehensive picture of glucose trends throughout the day and night.
The CGM market is projected to grow at a CAGR of 2% from 2024 to 2031, surpassing traditional glucose meters. Dexcom, Abbott, and Medtronic lead the CGM space, each developing new AI-powered features. These devices display real-time glucose values, trend arrows indicating the direction and speed of glucose changes, and alerts for high or low glucose levels.
CGM data reveals patterns that would be impossible to detect with traditional fingerstick testing. Users can see how different foods affect their glucose, how long insulin takes to work, and whether their basal insulin is adequate overnight. This information enables highly personalized insulin adjustments based on individual glucose response patterns.
Dexcom already submitted an application to the FDA for a 15-day sensor for the G7 CGM, so we anticipate approval in 2025. Current wear time for the G7 is 10.5 days, so this would add five additional days of monitoring and would cut the number of sensors needed per month from three to two. Dexcom’s over-the-counter CGM Stelo (for people with type 2 diabetes not on insulin) was already cleared for a 15-day sensor.
Flash Glucose Monitoring
Flash glucose monitoring (FGM) systems require users to scan a sensor to obtain glucose readings rather than receiving continuous automatic updates. While CGM is better suited for intensive diabetes management, FGM provides a lower-cost, flexible alternative for patients looking for occasional monitoring without constant alerts. FGM still provides valuable trend information and eliminates the need for routine fingerstick testing.
Time in Range Metrics
CGM technology has introduced new metrics for assessing glucose control beyond HbA1c. Time in range (TIR) measures the percentage of time glucose remains within the target range, typically 70-180 mg/dL. Time below range (TBR) and time above range (TAR) provide additional insights into hypoglycemia and hyperglycemia patterns.
These metrics offer more actionable information for insulin adjustment than HbA1c alone. A person might have an acceptable HbA1c but significant glucose variability with frequent highs and lows. TIR metrics reveal this variability and guide adjustments to improve glucose stability. The goal is typically to achieve at least 70% time in range while minimizing time below range to less than 4%.
Glucose Variability Assessment
CGM data enables assessment of glucose variability, which is increasingly recognized as an important aspect of diabetes management. High glucose variability, even with acceptable average glucose levels, is associated with increased risk of complications and hypoglycemia. Coefficient of variation (CV) is a key metric, with a target of less than 36% indicating stable glucose control.
Reducing glucose variability often requires fine-tuning insulin doses, adjusting I:C ratios for different meals, optimizing basal insulin timing, and addressing factors like meal composition and physical activity. CGM data makes this level of personalization possible by revealing the specific patterns contributing to variability.
Smart Insulin Delivery Systems
Technology has advanced beyond glucose monitoring to include intelligent insulin delivery systems that integrate monitoring data with insulin administration.
Connected Insulin Pens
For individuals who require intensive insulin therapy but do not wish to use an insulin pump, advances in insulin pens allow them to continue on injection therapy with “connected” insulin pens that offer connectivity with CGM and some BGM meters, built-in memory, and download capability. Similar integrations of continuous glucose monitoring and connected blood glucose meter data into “smart” pens have lessened the guesswork of intensive insulin management.
Smart insulin pens track dose timing and amounts, calculate recommended doses based on current glucose and carbohydrate intake, and account for insulin on board to prevent stacking. They sync with smartphone apps and CGM systems to provide comprehensive diabetes management tools without requiring pump therapy. This technology brings many benefits of automated insulin delivery to people who prefer injections.
Automated Insulin Delivery Systems
Advances in connected continuous glucose monitoring devices, insulin pumps, and insulin pens have led to the development of automated insulin delivery systems that modulate insulin infusion based on sensor glucose data. Automated insulin delivery (AID) systems, also called hybrid closed-loop systems, use algorithms to automatically adjust basal insulin delivery based on CGM readings.
This study evaluates the effectiveness of four commercially available automated insulin delivery (AID) systems in routine clinical practice for type 1 diabetes management and compares their first-year outcomes. These systems represent a significant advancement in personalized insulin therapy, as they continuously adapt insulin delivery to individual glucose patterns.
AID systems are continuing to advance, with improved opportunities to tighten glycemic control (such as with the twiist AID system, which features more tunable parameters than any other device currently available), and reduce burden (such as with the iLet AID system, which requires only weight to initiate and does not utilize specific carbohydrate counting for mealtime insulin dosing).
Current AID systems still require user input for meals and corrections, but they handle basal insulin adjustments automatically. This automation reduces the burden of diabetes management while improving glucose control and reducing hypoglycemia. Users still need to count carbohydrates and announce meals, but the system handles the complex task of adjusting background insulin throughout the day and night.
Emerging Fully Closed-Loop Systems
Research continues toward fully closed-loop systems that require minimal user interaction. These advanced systems aim to manage both basal and bolus insulin automatically, detecting meals through glucose patterns rather than requiring manual announcement. Some experimental systems incorporate multiple hormones, such as insulin and glucagon, to provide even tighter control with reduced hypoglycemia risk.
GlyTwin helps people with type 1 diabetes (T1D) avoid blood sugar spikes. Offers tailored insulin/food advice to discover what works best for each person. GlyTwin worked better than other tools to stop highs, making diabetes care easier and safer. Artificial intelligence and machine learning are being incorporated into these systems to learn individual patterns and optimize insulin delivery with increasing precision over time.
Lifestyle Factors and Insulin Personalization
Effective insulin personalization must account for the many lifestyle factors that influence glucose levels and insulin requirements.
Dietary Considerations
Diet profoundly affects insulin requirements. The amount, type, and timing of carbohydrate intake directly impact postprandial glucose excursions. However, protein and fat also influence glucose levels, particularly in larger quantities or with high-fat meals that can delay and extend glucose absorption.
Personalized insulin therapy considers individual dietary patterns and preferences. Someone following a low-carbohydrate diet will have very different insulin needs than someone consuming a higher-carbohydrate diet. Meal timing matters too—people who eat three structured meals daily require different insulin strategies than those who graze throughout the day or practice intermittent fasting.
The glycemic index and glycemic load of foods affect how quickly carbohydrates raise glucose levels. High-fiber foods, whole grains, and foods with lower glycemic indices cause slower, more gradual glucose rises compared to refined carbohydrates and sugary foods. Some individuals adjust their I:C ratios or use extended bolus features on insulin pumps to better match insulin action with slower-absorbing meals.
Physical Activity and Exercise
Physical activity significantly impacts insulin sensitivity and glucose levels. Exercise increases glucose uptake by muscles, often lowering blood glucose during and after activity. However, the effect varies based on exercise type, intensity, duration, and timing relative to meals and insulin doses.
Aerobic exercise typically lowers glucose levels, while high-intensity or anaerobic exercise may initially raise glucose due to stress hormone release. The timing of exercise relative to insulin administration matters greatly—exercising when rapid-acting insulin is peaking increases hypoglycemia risk.
Personalized insulin plans account for regular physical activity patterns. Athletes or very active individuals may need lower basal insulin doses and different I:C ratios than sedentary individuals. Many people reduce their bolus insulin dose before exercise or consume additional carbohydrates to prevent hypoglycemia. CGM systems are particularly valuable for monitoring glucose during and after exercise to understand individual response patterns.
Sleep and Circadian Rhythms
Sleep quality and circadian rhythms influence glucose metabolism and insulin sensitivity. Many people experience the dawn phenomenon, where glucose rises in the early morning hours due to hormonal changes. This pattern may require higher basal insulin doses in the early morning or a second basal insulin injection.
Shift workers face particular challenges with insulin management due to disrupted circadian rhythms and irregular meal timing. Personalized plans for shift workers must account for changing sleep schedules and may require different insulin regimens for work days versus days off.
Sleep deprivation and poor sleep quality can increase insulin resistance and make glucose control more difficult. Addressing sleep issues is an important component of comprehensive diabetes management and may reduce insulin requirements.
Stress and Illness
Stress, whether physical or emotional, triggers the release of counter-regulatory hormones like cortisol and adrenaline that raise blood glucose and increase insulin resistance. Chronic stress can significantly increase insulin requirements, while acute stress may cause unpredictable glucose fluctuations.
Illness, particularly infections and inflammatory conditions, typically increases insulin needs substantially. Infection and glucocorticoids increase insulin needs; renal insufficiency decreases insulin needs. Sick day management protocols are essential components of personalized insulin plans, providing guidance for increasing insulin doses during illness while monitoring for ketones and dehydration.
Medications can also affect insulin requirements. Corticosteroids dramatically increase insulin resistance and glucose levels. Glucocorticoids may dramatically increase postprandial BG levels but have little effect on gluconeogenesis (fasting glucose levels). Anticipate post-prandial hyperglycemia by increasing the nutritional insulin doses. The insulin dose will typically increase by 50% from before glucocorticoid use.
Special Populations and Personalization Considerations
Certain populations require special considerations when personalizing insulin therapy.
Older Adults
Recommendations 13.8a, 13.8b, and 13.8c emphasize personalized glycemic goals for older adults with intermediate or complex health conditions. Older adults often have multiple comorbidities, polypharmacy, and increased risk of hypoglycemia. Cognitive impairment may affect the ability to manage complex insulin regimens.
Personalized insulin plans for older adults often prioritize safety over tight control, with less stringent glucose targets to reduce hypoglycemia risk. Simplified regimens may be preferred, and Recommendations 13.16a through 13.16d focus on deintensifying therapy, especially medications that can cause hypoglycemia, and suggest switching to lower-risk medications.
Pediatric Patients
Children and adolescents with diabetes face unique challenges including growth, variable activity levels, unpredictable eating patterns, and developmental issues affecting self-management. Recommendation 14.4 discusses the importance of education regarding the need for insulin dosing adjustments according to meal composition.
Insulin requirements change dramatically during growth spurts and puberty due to growth hormone effects. Adolescents often experience increased insulin resistance requiring higher doses. Personalized plans must be flexible enough to accommodate these changes while supporting the transition to independent self-management.
Youth enrolled in 4T Study 1 (2020–2022) had a 1.1 % improvement in A1C and an increase from 28 % to 64 % meeting an A1C < 7 % at one year compared with historic control subjects. This demonstrates the effectiveness of personalized, technology-enabled insulin management in pediatric populations.
Pregnancy
Pregnancy dramatically affects insulin requirements due to hormonal changes. Insulin needs typically decrease in the first trimester, then increase substantially in the second and third trimesters as placental hormones increase insulin resistance. Tight glucose control is essential during pregnancy to reduce risks to both mother and baby.
Personalized insulin management during pregnancy requires frequent dose adjustments, often weekly or even more frequently. CGM is particularly valuable for achieving tight control while minimizing hypoglycemia risk. Insulin requirements drop precipitously after delivery, requiring immediate dose reductions to prevent severe hypoglycemia.
Individuals with Kidney Disease
Kidney disease affects insulin metabolism and clearance, typically reducing insulin requirements as kidney function declines. Renal insufficiency decreases insulin needs. People with chronic kidney disease require careful insulin dose adjustments and close monitoring to prevent hypoglycemia.
As kidney function worsens, insulin doses often need to be reduced by 25-50% or more. The risk of hypoglycemia increases because the kidneys normally clear insulin from the bloodstream. Personalized plans must account for changing kidney function and adjust doses accordingly.
Overcoming Barriers to Insulin Therapy
Despite the effectiveness of insulin therapy, many barriers prevent optimal use and personalization.
Psychological Insulin Resistance
Many people with type 2 diabetes resist starting insulin therapy due to fear of injections, concerns about hypoglycemia, perceived failure, or belief that insulin means their diabetes is severe. Healthcare providers must address these concerns through education and support.
Provide information on benefits (e.g., more “natural” versus pills, dosing flexibility). Consider suggesting a “trial” (e.g., for one month). Compare the relative ease of using newer insulin devices (e.g., pen, smaller needle) versus syringe or vial. Framing insulin as a powerful tool for improving health rather than a punishment can help overcome resistance.
Complexity and Burden
Insulin therapy can be complex and burdensome, requiring multiple daily injections, frequent glucose monitoring, carbohydrate counting, and dose calculations. This complexity contributes to suboptimal adherence and glucose control.
Simplifying regimens when possible improves adherence. Starting with basal insulin only, using premixed insulins, or employing simplified meal-based dosing rather than carbohydrate counting can reduce burden while still improving control. As patients gain confidence and experience, regimens can be intensified if needed.
Technology helps reduce burden through automated calculations, dose tracking, and integration of monitoring and delivery systems. The differences in features and functionality give users the ability to select the devices that best meet their unique requirements and preferences. This article provides information about the functionality and availability of various continuous glucose monitors, insulin delivery devices, and connected digital health apps.
Cost and Access
The cost of insulin, devices, and supplies remains a significant barrier for many people. Insurance coverage varies widely, and out-of-pocket costs can be prohibitive. This financial burden may lead to insulin rationing, which is dangerous and can result in serious complications.
Healthcare providers should be aware of cost issues and work with patients to find affordable options. This might include prescribing less expensive insulin formulations, connecting patients with patient assistance programs, or using older but still effective technologies when newer options are unaffordable.
Fear of Hypoglycemia
Insulin use is associated with hypoglycemia and weight gain. Of patients taking insulin, 7% to 15% experience at least one episode of hypoglycemia per year. Fear of hypoglycemia is a major barrier to optimal insulin use and can prevent appropriate dose intensification.
Addressing hypoglycemia fear requires education about recognition and treatment, careful dose titration to minimize risk, and use of technologies like CGM that provide early warning of dropping glucose levels. Involving family members in hypoglycemia management and ensuring patients have glucagon available for emergencies also helps reduce fear.
The Role of Diabetes Education and Support
Comprehensive diabetes education is essential for successful personalized insulin therapy. Patients need knowledge and skills to implement complex insulin regimens safely and effectively.
Structured Education Programs
Structured diabetes self-management education programs teach essential skills including glucose monitoring, insulin administration, carbohydrate counting, dose calculation, hypoglycemia recognition and treatment, sick day management, and problem-solving. These programs significantly improve glucose control and reduce complications.
Education should be individualized based on the patient’s regimen, literacy level, learning style, and cultural background. Hands-on practice with insulin devices, glucose meters, and dose calculations helps build confidence and competence. Ongoing education and reinforcement are necessary as regimens evolve and new technologies become available.
The Diabetes Care Team
Optimal insulin personalization requires a multidisciplinary team approach. Endocrinologists or primary care physicians prescribe insulin and oversee medical management. Certified diabetes care and education specialists provide education and support for self-management. Registered dietitians help with meal planning and carbohydrate counting. Pharmacists ensure proper medication use and can assist with cost issues.
Regular follow-up with the diabetes care team is essential for reviewing glucose data, adjusting insulin doses, addressing problems, and providing ongoing support. Telehealth has expanded access to diabetes care, allowing for more frequent check-ins and dose adjustments without requiring in-person visits.
Peer Support and Community
Connecting with others who have diabetes provides valuable emotional support and practical advice. Peer support groups, whether in-person or online, allow people to share experiences, learn from each other, and feel less isolated in managing their condition. Many people find that peer support complements professional healthcare and improves their ability to manage insulin therapy effectively.
Emerging Technologies and Future Directions
The field of diabetes technology continues to evolve rapidly, with new innovations promising even better personalization of insulin therapy.
Artificial Intelligence and Machine Learning
AI-powered diabetes management tools and personalized digital health platforms are emerging as innovators in diabetes care. Artificial intelligence algorithms can analyze vast amounts of glucose data to identify patterns, predict future glucose levels, and recommend insulin dose adjustments with increasing accuracy.
Machine learning systems can learn individual glucose response patterns and provide increasingly personalized recommendations over time. These systems may eventually be able to predict the impact of meals, exercise, and other factors on glucose levels and suggest proactive insulin adjustments to prevent excursions before they occur.
Integrated Biosensing Platforms
Diabetes technology will take center stage in 2025, with the introduction of continuous ketone monitoring, integrated biosensing to elevate personalized health insights. A new CGM that measures both blood sugar and ketones is closer than ever. Future sensors may measure multiple biomarkers simultaneously, providing a more complete picture of metabolic status to guide insulin therapy.
Implantable and Long-Duration Sensors
Implantable CGM systems that last for months or even a year are in development. The Eversense 365 implantable CGM was approved in 2024 with an iCGM designation, so it’s ready to connect with a pump partner. These long-duration sensors would reduce the burden of frequent sensor changes and potentially provide more accurate readings.
Smart Insulin and Glucose-Responsive Insulin
Researchers are developing “smart” insulins that would automatically activate in response to rising glucose levels and deactivate when glucose falls. These glucose-responsive insulins could dramatically reduce hypoglycemia risk while improving glucose control, essentially creating a chemical closed-loop system without requiring electronic devices.
Cell-Based Therapies
The most dramatic breakthrough in diabetes cure research came in 2024 when a woman in China became the first person to achieve sustained insulin independence using stem cells derived from her own body. Researchers at Peking University extracted cells from a patient, converted them to induced pluripotent stem cells (iPSCs), then differentiated them into beta cells.
Type 1 diabetes research will continue to move toward a functional cure as Vertex enters pivotal trials for their stem cell-derived islet cell therapy. While still experimental, these therapies represent the ultimate personalization—restoring the body’s own insulin production and potentially eliminating the need for exogenous insulin therapy entirely.
Practical Implementation: Creating Your Personalized Insulin Plan
Translating evidence-based principles into a practical, personalized insulin plan requires systematic assessment, implementation, and ongoing refinement.
Initial Assessment and Goal Setting
Begin by conducting a comprehensive assessment of current glucose control, lifestyle factors, and treatment goals. Review recent HbA1c values, glucose monitoring data, current medications, and any history of hypoglycemia or hyperglycemia. Discuss the patient’s daily routine, meal patterns, physical activity, work schedule, and any barriers to diabetes management.
Establish individualized glucose targets based on age, diabetes duration, comorbidities, hypoglycemia risk, and patient preferences. A fasting and premeal blood glucose goal of 80 to 130 mg per dL and a two-hour postprandial goal of less than 180 mg per dL are recommended. However, these targets may need modification for certain populations.
Selecting the Appropriate Regimen
Choose an insulin regimen that balances effectiveness with feasibility for the individual patient. Consider starting with a simpler regimen and intensifying as needed rather than beginning with a complex regimen that may overwhelm the patient. The American Diabetes Association suggests the use of long-acting (basal) insulin to augment therapy with one or two oral agents or one oral agent plus a glucagon-like peptide 1 receptor agonist when the A1C level is 9% or more.
For type 1 diabetes or advanced type 2 diabetes, a basal-bolus regimen typically provides the best control and flexibility. For less advanced type 2 diabetes, starting with basal insulin alone may be appropriate, with the option to add mealtime insulin later if needed.
Calculating Initial Doses
Calculate initial insulin doses using weight-based formulas as a starting point. For basal insulin, begin conservatively to minimize hypoglycemia risk, typically 0.1-0.2 units/kg for type 2 diabetes or 0.2-0.3 units/kg for type 1 diabetes. For basal-bolus regimens, divide the total daily dose with approximately 40-50% as basal insulin and the remainder divided among meals.
Calculate initial I:C ratios and correction factors using the 500 rule and 1800 rule respectively. Recognize that these are starting points that will require adjustment based on individual response.
Education and Training
Provide comprehensive education on insulin administration technique, glucose monitoring, dose calculation, hypoglycemia recognition and treatment, and when to contact the healthcare team. Ensure the patient can demonstrate proper technique and understands the rationale for their regimen.
For patients using carbohydrate counting, provide thorough training in identifying carbohydrate-containing foods, reading nutrition labels, and estimating portion sizes. For those using simplified meal-based dosing, teach how to categorize meals as small, usual, or large and how to adjust doses accordingly.
Monitoring and Data Collection
Establish a monitoring schedule that provides sufficient data for pattern identification without being overly burdensome. For basal-only regimens, fasting glucose monitoring may be sufficient initially. For basal-bolus regimens, premeal and bedtime monitoring is typically recommended, with periodic postprandial checks.
CGM provides the most comprehensive data and is increasingly accessible. When available, CGM should be strongly considered as it provides insights impossible to obtain through fingerstick testing alone.
Systematic Dose Adjustment
Review glucose data regularly to identify patterns requiring dose adjustments. Focus on one component of the regimen at a time—adjust basal insulin first to achieve stable fasting glucose, then optimize bolus doses for individual meals.
Make small, incremental adjustments and allow sufficient time (typically 3-7 days) to assess the effect before making additional changes. Document all dose changes and the rationale behind them to track what works and what doesn’t.
Ongoing Refinement and Support
Schedule regular follow-up appointments to review progress, adjust doses, address problems, and provide ongoing support. Initially, more frequent contact may be needed—weekly or biweekly—until the regimen is optimized. Once stable, quarterly visits are typically sufficient, though more frequent contact may be needed during illness, major lifestyle changes, or when problems arise.
Encourage patients to contact the healthcare team between visits when questions or concerns arise. Establish clear guidelines for when to seek urgent advice, such as persistent hyperglycemia, frequent hypoglycemia, or illness.
Measuring Success: Beyond HbA1c
While HbA1c remains an important measure of overall glucose control, personalized insulin therapy should be evaluated using multiple metrics that capture different aspects of diabetes management.
Glycemic Metrics
HbA1c provides an average glucose level over 2-3 months but doesn’t reveal glucose variability or hypoglycemia. CGM-derived metrics like time in range, time below range, time above range, and coefficient of variation provide a more complete picture. The goal is to maximize time in range while minimizing time below range and reducing glucose variability.
Hypoglycemia Frequency and Severity
Track the frequency and severity of hypoglycemic episodes. Any increase in hypoglycemia frequency should prompt regimen review and adjustment. Severe hypoglycemia requiring assistance is particularly concerning and necessitates immediate intervention to prevent recurrence.
Quality of Life and Treatment Satisfaction
Adherence and Self-Management Behaviors
Monitor adherence to the insulin regimen, glucose monitoring, and other self-management behaviors. Poor adherence may indicate that the regimen is too complex, burdensome, or doesn’t fit the patient’s lifestyle. Rather than blaming the patient, consider how the regimen might be modified to improve feasibility.
Conclusion: The Path Forward
Personalizing insulin therapy represents the gold standard in diabetes management. By tailoring insulin regimens to individual physiological characteristics, lifestyle patterns, preferences, and goals, healthcare providers can help patients achieve optimal glucose control while minimizing burden and maximizing quality of life.
The evidence clearly supports personalized approaches over one-size-fits-all protocols. Individual assessment, appropriate regimen selection, evidence-based dose calculation, systematic adjustment strategies, and comprehensive education form the foundation of successful personalized insulin therapy.
Modern technologies including CGM, smart insulin pens, and automated insulin delivery systems have made personalization more achievable than ever before. These tools provide unprecedented insights into glucose patterns and enable precise insulin adjustments that were impossible with traditional approaches. As technology continues to advance, with artificial intelligence, ultra-long-acting insulins, and potentially curative cell-based therapies on the horizon, the future of personalized insulin therapy looks increasingly promising.
However, technology alone is not sufficient. Successful personalization requires a collaborative partnership between patients and healthcare teams, comprehensive education and support, attention to psychological and social factors, and ongoing refinement based on real-world outcomes. The goal is not just better numbers, but better lives—enabling people with diabetes to thrive while managing their condition effectively.
For healthcare providers, embracing personalized insulin therapy means moving beyond protocol-driven care to truly individualized treatment planning. It requires taking time to understand each patient’s unique circumstances, preferences, and challenges. It means being willing to try different approaches, learn from what works and what doesn’t, and continuously refine the plan based on outcomes.
For people with diabetes, personalized insulin therapy offers hope for better control without sacrificing quality of life. It recognizes that diabetes management must fit into life, not the other way around. With the right regimen, education, support, and tools, most people with diabetes can achieve their glucose targets while maintaining the flexibility to live full, active lives.
The journey to optimal insulin therapy is rarely linear. It involves trial and error, setbacks and successes, and ongoing learning and adjustment. But with persistence, collaboration, and evidence-based approaches, personalized insulin therapy can transform diabetes management from a burden into a manageable aspect of daily life, enabling better health outcomes and improved well-being for people living with diabetes.
Additional Resources
For more information on personalizing insulin therapy and diabetes management, consider exploring these reputable resources:
- American Diabetes Association (https://www.diabetes.org) – Comprehensive diabetes information, including the annual Standards of Care guidelines
- JDRF (https://www.jdrf.org) – Type 1 diabetes research and advocacy organization with extensive educational resources
- Beyond Type 1 (https://www.beyondtype1.org) – Community and educational resources for people with type 1 diabetes
- DiaTribe (https://www.diatribe.org) – News and information about diabetes devices, treatments, and research
- Association of Diabetes Care & Education Specialists (https://www.diabeteseducator.org) – Find certified diabetes care and education specialists in your area
Working with your healthcare team and utilizing evidence-based approaches to personalize your insulin therapy can lead to significantly improved outcomes and quality of life. The investment in developing a truly individualized plan pays dividends in better glucose control, reduced complications, and the freedom to live life on your terms while effectively managing diabetes.